Obinutuzumab + Bendamustine (GADOLIN)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-OBINUTUZUMAB DRUG-BENDAMUSTINE |
|---|
| ID | REG-OBINUTUZUMAB-BENDA |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-05-09 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-GADOLIN-SEHN-2016 SRC-NCCN-BCELL-2025 |
Notes
GADOLIN schedule: OBG+Benda induction × 6 cycles (28-day) → obinutuzumab maintenance 1000 mg IV q2months × 2yr for rituximab-refractory iNHL (predominantly FL grades 1-3a). Type II anti-CD20 (glyco-engineered GA101): enhanced ADCC, direct cell death vs rituximab. PFS HR 0.55 (Sehn 2016) + OS HR 0.67 (Cheson 2018, PMID 29584548). HBV reactivation screening + entecavir prophylaxis mandatory. PJP prophylaxis ≥6 mo post-anti-CD20 therapy. Maintenance OBG modeled in the indication, not as a separate regimen.
Used By
Indication
IND-FL-2L-OBG-BENDA- IND-FL-2L-OBG-BENDA